Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDRESS trial of subcutaneous efgartigimod PH20 in adult pemphigus
2020-002915-23Phase 3Completed
- Sponsor
- argenx
- Start
- Aug 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) comparing Efgartigimod PH20 SC with Placebo (2 arms). Started Aug 2020; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on 2020-002915-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002915-23.